IPO UPDATE: Intrexon rises 81% in 2 days; also Sophiris, Ruthigen, Acceleron, Iroko
This article was originally published in Scrip
Executive Summary
Intrexon chairman and CEO Randal Kirk took a page from Quintiles executive chairman Dennis Gillings's playbook and cashed in on his investments in the synthetic biology company with an initial public offering that increased the majority shareholder's net worth by another $1 billion.
You may also be interested in...
Finance Watch: Intrexon Reorganizes, Raises Cash And Becomes Precigen
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
Finance Watch: Regulus Shrinks To Preserve Cash, Ironwood Cuts Jobs Ahead Of Split
Public Company Edition: Long-struggling Regulus is laying off employees and pausing its two clinical programs. Also, Ironwood is shuffling staff ahead of splitting into two companies and will cut 40 jobs in the process. And among several loan agreements and note sales, Tesaro borrows another $200m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.